Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

New York, New York-- (Newsfile Corp. - February 7, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...

US stocks erased early trading gains on Friday as treasury yields rose and investors digested a highly anticipated monthly ...

US stock futures hit pause on Friday as investors braced for the highly anticipated monthly jobs report and digested Amazon's ...

Contracts on the S&P 500 ( ES=F) and the tech-heavy Nasdaq 100 ( NQ=F) were down 0.2%. Dow Jones Industrial Average futures ( ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...